AVAX Technologies
Founded Year
1990Stage
Unattributed VC - IV | AliveTotal Raised
$39.27MLast Raised
$3.05M | 19 yrs agoAbout AVAX Technologies
AVAX Technologies is a Healthcare/Biotechnology company based in Philadelphia, Pennsylvania. AVAX Technologies' investors include Precept Capital Management, Essex Woodland Health Ventures, PKB Privatbank AG, Soros Fund Management, Pequot Capital Mangement, Bank Julius Baer and Perot Investments.
Missing: AVAX Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AVAX Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing AVAX Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AVAX Technologies is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
AVAX Technologies Patents
AVAX Technologies has filed 1 patent.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/26/2013 | Vaccines, Clusters of differentiation, Immunology, Experimental cancer drugs, Oncology | Application |
Application Date | 7/26/2013 |
---|---|
Grant Date | |
Title | |
Related Topics | Vaccines, Clusters of differentiation, Immunology, Experimental cancer drugs, Oncology |
Status | Application |
Latest AVAX Technologies News
Mar 20, 2017
AVAX Technologies Inc. (Kansas City, MO) and the University of Tokyo have entered into a collaborative research agreement to evaluate the application of the AVAX's patented AC Vaccine technology for the treatment of breast cancer. As part of the agreement, AVAX will provide the university with access to its technology in order to manufacture the vaccine for a clinical trial in Japan. The trial will be supported in part by a grant from the Noguchi Medical Foundation. AVAX's AC Vaccine technology is made from a patient's own cancer cells by modifying the tumor cells with a molecule called a hapten. This process, known as haptenization, alters the tumor cells and makes them appear foreign to the patient's immune system. When the hapten-modified cells are reinjected into patients, they stimulate the immune system to recognize the cancer cells and destroy them. AVAX is conducting a pivotal registration trial of the vaccine in malignant melanoma (M-Vax) and a Phase I/II trial in ovarian cancer (O-Vax) in the U.S. The collaborative research agreement with the University of Tokyo extends clinical development of the technology to a third indication. AVAX Technologies Inc. specializes in the development and commercialization of novel biotechnologies, immunotherapies, and pharmaceuticals for cancer and other life-threatening diseases. For more information: Jeffrey M. Jonas, President and CEO, AVAX Technologies Inc., 4520 Main St., Ste. 930, Kansas City, MO 64111. Tel: 816-960-1333. Fax: 816-960-1334. Like what you are reading? Sign up for our free newsletter SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy .
AVAX Technologies Frequently Asked Questions (FAQ)
When was AVAX Technologies founded?
AVAX Technologies was founded in 1990.
Where is AVAX Technologies's headquarters?
AVAX Technologies's headquarters is located at 2000 Hamilton Street, Philadelphia.
What is AVAX Technologies's latest funding round?
AVAX Technologies's latest funding round is Unattributed VC - IV.
How much did AVAX Technologies raise?
AVAX Technologies raised a total of $39.27M.
Who are the investors of AVAX Technologies?
Investors of AVAX Technologies include BNP Paribas, Matignon Technologies, Credit Suisse, FGS Advisors, SG Private Equity and 12 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.